Ph.D., Vice President, Research & Development; OncoResponse, Inc.
Kamal D. Puri has more than 20 years of research and development experience in immunology, oncology, and neurobiology. Dr. Puri joined OncoResponse from Celgene, where he discovered new molecular entities for the immunology pipeline and identified and supported new indications for portfolio molecules. Prior to Celgene, Dr. Puri was Associate Director of Research at Gilead and contributed to the approval of Zydelig™ a first-in-class PI3K delta inhibitor for the treatment of hematological malignancies, and he led efforts for a best-in-class PI3K delta inhibitor and advanced it into clinical development, and directed research efforts on multiple discovery projects in inflammation. Prior to Gilead, Dr. Puri was Head of Biology at Calistoga Pharma, where he was responsible for a wide range of activities with success in advancing three drug candidates into clinical development for multiple indications. Dr. Puri undertook his immunology training with Timothy A. Springer, Ph.D. at the Harvard Medical School.
Presentation Title and Company Description
Immunotherapy Showcase: Discovering Cancer Antibodies from Elite Super Responders
OncoResponse, in a broad strategic alliance with MD Anderson uses a proprietary B-cell technology platform to mine the immune system of cancer patients who have responded to immunotherapies to discover novel antibodies to develop therapeutic monoclonal antibodies to treat cancer.